[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
Peter L. Bonate, "Pharmacokinetics in Drug Development: Advances and Applications, Volume 3"
Publisher: S/////er | 2011 | ISBN: 1441979360 | PDF | 332 pages | 5.4 MB
The topics chosen for this volume were selected because they are some of
the current development or technological issues facing drug development
project teams. They regard the practical considerations for assessment
of selected special development populations. For example, they include
characterization of drug disposition in pregnant subjects, for
measuring arrhythmic potential, for analysis tumor growth modeling, and
for disease progression modeling. Practical considerations for
metabolite safety testing, transporter assessments, Phase 0 testing, and
development and execution of drug interaction programs reflect current
regulatory topics meant to address enhancement of both safety assessment
and early decision-making during new candidate selection. Important
technologies like whole body autoradiography, digital imaging and dried
blood spot sample collection methods are introduced, as both have begun
to take a more visible role in pharmacokinetic departments throughout
the industry.
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
Peter L. Bonate, "Pharmacokinetics in Drug Development: Advances and Applications, Volume 3"
Publisher: S/////er | 2011 | ISBN: 1441979360 | PDF | 332 pages | 5.4 MB
The topics chosen for this volume were selected because they are some of
the current development or technological issues facing drug development
project teams. They regard the practical considerations for assessment
of selected special development populations. For example, they include
characterization of drug disposition in pregnant subjects, for
measuring arrhythmic potential, for analysis tumor growth modeling, and
for disease progression modeling. Practical considerations for
metabolite safety testing, transporter assessments, Phase 0 testing, and
development and execution of drug interaction programs reflect current
regulatory topics meant to address enhancement of both safety assessment
and early decision-making during new candidate selection. Important
technologies like whole body autoradiography, digital imaging and dried
blood spot sample collection methods are introduced, as both have begun
to take a more visible role in pharmacokinetic departments throughout
the industry.
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
